Literature DB >> 7305325

Fosfomycin kinetics after intravenous and oral administration to human volunteers.

M Goto, M Sugiyama, S Nakajima, H Yamashina.   

Abstract

The pharmacokinetics of fosfomycin, administered intravenously and orally at two different doses (20 and 40 mg/kg of body weight), was studied in seven volunteers. The elimination profile of this antibiotic, when administered intravenously, followed a two-compartment kinetic model, independent of dosage, giving an elimination half-life of 2.23 +/- 0.62 h and an average total volume of distribution at steady state of 0.34 liter/kg. Peak serum levels after rapid intravenous administration of 20 and 40 mg/kg were 132.1 +/- 31.8 and 259.3 +/- 32.5 micrograms/ml, respectively. Peak serum levels after oral administration were 7.1 +/- 1.6 and 9.4 +/- 3.6 micrograms/ml for the 20 and 40 mg/kg doses, respectively. During the first 24 h after administration, an average of 80% of the intravenous doses and less than 25% of the oral doses were recovered in the urine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7305325      PMCID: PMC181707          DOI: 10.1128/AAC.20.3.393

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Antibiotic levels in experimentally infected mice in relation to therapeutic effect and antibacterial activity in vitro.

Authors:  D Merrikin; G N Rolinson
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

3.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

4.  Pharmacokinetic study of fosfomycin and its bioavailability.

Authors:  R Cadórniga; M Diaz Fierros; T Olay
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

5.  Using pharmacokinetics in drug therapy. VIII: Pharmacokinetic evaluation of antibiotic dosage regimens.

Authors:  J N Henricks; G E Schumacher
Journal:  Am J Hosp Pharm       Date:  1980-10

6.  Fosfomycin: Laboratory studies.

Authors:  H B Woodruff; J M Mata; S Hernández; S Mochales; A Rodríguez; E O Stapley; H Wallick; A K Miller; D Hendlin
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

7.  Fosfomycin, antimicrobial activity in vitro and in vivo.

Authors:  S Goto
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

8.  Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms.

Authors:  D D Shen; M Fixley; D L Azarnoff
Journal:  J Pharm Sci       Date:  1978-07       Impact factor: 3.534

9.  [A study on serum level and urinary excretion of fosfomycin-Na in man with special reference to pharmacokinetic analysis (author's transl)].

Authors:  N Kawabata; Y Shiraha; S Doi; K Umemura; K Yaginuma
Journal:  Jpn J Antibiot       Date:  1978-09

10.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

View more
  18 in total

1.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Authors:  E Wenzler; E J Ellis-Grosse; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics.

Authors:  M Trautmann; C Meincke; K Vogt; M Ruhnke; A M Lajous-Petter
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

4.  Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.

Authors:  Rujipas Sirijatuphat; Visanu Thamlikitkul
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.

Authors:  L V Perdigão-Neto; M S Oliveira; C F Rizek; C M D M Carrilho; S F Costa; A S Levin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

6.  Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.

Authors:  James Albiero; Sherwin K B Sy; Josmar Mazucheli; Silvana Martins Caparroz-Assef; Bruno Buranello Costa; Janio Leal Borges Alves; Ana Cristina Gales; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 7.  'Old' antibiotics for emerging multidrug-resistant bacteria.

Authors:  Phillip J Bergen; Cornelia B Landersdorfer; Hee Ji Lee; Jian Li; Roger L Nation
Journal:  Curr Opin Infect Dis       Date:  2012-12       Impact factor: 4.915

8.  Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.

Authors:  T Bergan
Journal:  Infection       Date:  1990       Impact factor: 3.553

9.  Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and Coresistance phenotype among recent Escherichia coli isolates from U.S. veterans.

Authors:  James R Johnson; Sarah M Drawz; Stephen Porter; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

10.  Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults.

Authors:  F Borsa; A Leroy; J P Fillastre; M Godin; B Moulin
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.